Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.26.1
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Product Information [Line Items]    
Total net revenue $ 1,351,527 $ 1,853,597
Health Care, Patient Service [Member]    
Product Information [Line Items]    
Total net revenue [1] 1,082,210 1,570,382
Histology Service Fees [Member]    
Product Information [Line Items]    
Total net revenue 250,516 263,754
Medical Director Fees [Member]    
Product Information [Line Items]    
Total net revenue 17,461 16,588
Department of Defense Observational Studies [Member]    
Product Information [Line Items]    
Total net revenue 1,131
Other Revenues [Member]    
Product Information [Line Items]    
Total net revenue $ 209 $ 2,873
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $361,000 and $169,000 for the three months ended March 31, 2026 and 2025, respectively.